Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fusion protein containing chimeric antigen receptor and application thereof

A chimeric antigen receptor and fusion protein technology, applied in the field of biomedicine, can solve the problems of lack of safe and special targets, complex tumor immune microenvironment, poor treatment effect, etc., and achieve enhanced anti-apoptosis and memory expression type, good potential for clinical application, and the effect of changing the immune microenvironment

Active Publication Date: 2021-12-10
SUN YAT SEN UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Based on the breakthrough of CAR T in the treatment of blood tumors, CAR T therapy has been further extended to the treatment of solid tumors, and has been explored in various solid tumors including breast cancer, liver cancer, colorectal cancer and lung cancer. Unlike hematological tumors, it lacks safe and specific targets, and solid tumors have a complex tumor immune microenvironment, which ultimately leads to poor therapeutic effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein containing chimeric antigen receptor and application thereof
  • Fusion protein containing chimeric antigen receptor and application thereof
  • Fusion protein containing chimeric antigen receptor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0071] 1. Construction of Sirf CAR T cells co-expressing SIRPα-Fc fusion protein

[0072] 1.1 Construction of T2-mCAR molecule co-expressing SIRPα-Fc

[0073] Among the numerous CD47 antibodies or receptor-blocking molecules, we selected the drug under investigation, SIRPα-Fc fusion protein (TTI-621). Compared to the 150 kDa antibody molecule, the molecular weight of SIRPα-Fc is only 90kDa , with better penetration and tissue distribution. And the human-derived SIRPα-Fc fusion protein has been confirmed to be able to bind to CD47 molecules on the surface of tumor cells in vitro, thereby enhancing the phagocytic function of macrophages and activating the anti-tumor function of the entire immune system. The mouse CAR gene constructed based on the retroviral vector backbone can be efficiently transduced into mouse T cells. We used the original mouse second-generation CAR molecule T2-m28z ( figure 2 On the basis of A) in A), the mCAR structure co-expressing SIRPα-Fc was constru...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to the field of biomedicine, in particular to a fusion protein containing a chimeric antigen receptor and its application. The fusion protein includes chimeric antigen receptor, 2A peptide, first signal peptide, Sirpα domain and IgG1 Fc in series; said chimeric antigen receptor comprises scFv region, hinge region, transmembrane domain and intracellular signal transduction Area. Sirf CAR T cells can reduce tumor burden, improve the survival rate of tumor-bearing mice, and have no obvious hematological toxicity and side effects, and have good potential for clinical application. SIRPα-Fc fusion protein can enhance the anti-apoptosis and memory phenotype of CAR T cells, and change the immune microenvironment of tumor tissue.

Description

technical field [0001] The present invention relates to the field of biomedicine, in particular, to a fusion protein containing a chimeric antigen receptor and its application. Background technique [0002] Malignant tumors have become one of the leading causes of death worldwide. With the continuous development of science and technology, the early diagnosis and treatment of cancer has been able to greatly improve the cure rate of cancer and improve the quality of life of patients. However, most malignant tumors still have problems such as poor prognosis and easy recurrence. Among all tumor treatment methods, immunotherapy has received constant attention and expectation from researchers. The biggest feature of immunotherapy is to use the immune system itself to fight cancer, including antibody therapy, cell therapy and immunomodulatory therapy. Among them, the particularly interesting cell therapy refers to the infusion of cell preparations into the patient, thereby activ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N5/10A61K39/00A61P35/00
CPCC07K14/70596C07K14/7051C07K14/70521C12N5/0636A61K39/001129A61P35/00C07K2319/30C07K2319/02C07K2319/03C07K2319/33C07K2319/00C12N2510/00A61K2039/5156
Inventor 黄朝峰陈焕鹏
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com